Somewhat Positive Media Coverage Somewhat Unlikely to Affect China Biologic Products (CBPO) Stock Price

News headlines about China Biologic Products (NASDAQ:CBPO) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. China Biologic Products earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.7620278163414 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of China Biologic Products (NASDAQ:CBPO) traded up $2.25 during trading on Wednesday, hitting $83.67. The company’s stock had a trading volume of 217,623 shares, compared to its average volume of 233,350. China Biologic Products has a fifty-two week low of $71.85 and a fifty-two week high of $120.46. The firm has a market capitalization of $2,700.00, a PE ratio of 35.16, a P/E/G ratio of 1.17 and a beta of 1.62.

China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.89 by $0.01. China Biologic Products had a return on equity of 21.30% and a net margin of 18.34%. The firm had revenue of $90.10 million during the quarter, compared to analysts’ expectations of $85.15 million. During the same quarter last year, the firm earned $0.95 earnings per share. The business’s revenue for the quarter was up 16.1% on a year-over-year basis. research analysts anticipate that China Biologic Products will post 5.09 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on CBPO shares. Deutsche Bank set a $105.00 price target on China Biologic Products and gave the stock a “buy” rating in a report on Friday, March 2nd. TheStreet cut China Biologic Products from a “b-” rating to a “c+” rating in a report on Thursday, March 1st. Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. Finally, BidaskClub raised China Biologic Products from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 20th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $122.50.

ILLEGAL ACTIVITY NOTICE: This article was first reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/2018/03/14/china-biologic-products-cbpo-receives-media-sentiment-score-of-0-22/1890334.html.

About China Biologic Products

China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Insider Buying and Selling by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.